



December 12, 2016
Announcement no. 26

Financial calendar 2017

February 15	Quiet period prior to the annual report begins
March 9	Deadline for shareholder proposals for Annual General Meeting
March 15	Annual report for 2016
April 21	Annual General Meeting
April 22	Quiet period prior to the Interim report begins
May 4	Interim report - 3 months 2017
July 27	Quiet period prior to the Interim report begins
August 10	Interim report - 6 months 2017
October 24	Quiet period prior to the Interim report begins
November 7	Interim report - 9 months 2017

Further information:

Gry Husby Larsen, General Counsel
Tel. no. (+45) 45 29 00 00, e-mail investor@bioporto.com

About BioPorto

BioPorto Diagnostics A/S is an in-vitro diagnostics company that provides healthcare professionals in clinical and research settings a range of diagnostic tests and antibodies. Our pioneering product portfolio includes assays for underserved disease states such as NGAL for acute kidney injury. We sell our products in more than 80 countries through diverse sales channels and partners. BioPorto has its headquarters in Copenhagen, Denmark and is listed on the Nasdaq Copenhagen stock exchange.